Neogen Chemicals reports Q2 FY27 revenues of ₹296 crore, 42% YoY growth
Neogen Chemicals · Chemicals & Petrochemicals
What the filing says
- Q2 FY27 consolidated EBITDA ₹45 crore, up 51% YoY; PAT ₹8 crore, up 144% YoY
- Raised INR 600 crore via first-ever QIP, oversubscribed 6.5x
- CRISIL revised outlook on long-term bank facilities and NCDs to 'CRISIL A-/Stable' from 'Negative'
Why it's rated major development: the year-on-year change is 144% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Neogen Chemicals
- Fundraise / allotmentMajor developmentNeogen Chemicals reports Q2 FY 2026-27 results and QIP fund utilization update
- Fundraise / allotmentMajor developmentNeogen Chemicals Sept-quarter results, ₹600 crore QIP and ₹200 crore NCD redemption plan
- Fundraise / allotmentMajor developmentNeogen Chemicals Q2 FY2026-27: QIP completed, standalone profit rises to ₹21.14 crore
- Fundraise / allotmentNotableNeogen Chemicals raises ~₹600 crore via first-ever QIP, oversubscribed over 6.5x
- Fundraise / allotmentNotableNeogen Chemicals completes QIP allotment of 26.6 lakh equity shares at ₹2,255 each
Other fundraise / allotment filings this fortnight
- Grand Oak Canyons board to consider Rs. 20,67,00,00,000 NCPS allotment on 5 Nov
- Aarti Industries shareholders approve special resolution to raise up to ₹1,000 crore
- Ola Electric approves allotment of 37,02,72,665 partly paid shares in rights issue
- Evonile Pharma receives BSE in-principle approval for ₹900 crore rights issue
- Evonile Pharma receives BSE approval for ₹90 crore Rights Issue, board meeting set
- Aptus Pharma receives BSE in-principle approval for preferential equity issue
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.